AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood

Recruitingn/aAges 18 Years - 75 YearsAllSecond Affiliated Hospital, Zhejiang University, โ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

By collecting blood samples from liver cancer patients and healthy individuals, and comparing the blood protein profiles of the two, the biomarkers for early diagnosis and tissue traceability were identified to accurately establish an early diagnosis model for liver cancer and verify its efficacy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Voluntarily sign informed consent. 2. Male or female, age equal to or greater than 18 years and less than 75 years. 3. Patients with liver cancer who have been diagnosed or suspected for the first time within 42 days prior to blood collection 4. The subject has not undergone any local or systemic anti-tumor therapy before blood collection, including (but not limited to) tumor surgical treatment for any purpose, local or systemic chemoradiotherapy, targeted therapy (including anti-angiogenic drugs), immunotherapy, cancer vaccine and hormone therapy, etc. 5. Patients with histologically or cytological, radiographically confirmed hepatocellular carcinoma. Exclusion Criteria: 1. Female subjects who are pregnant or breastfeeding. 2. Previous organ transplantation or non-autologous bone marrow or stem cell transplantation. 3. Received drugs with anti-tumor effects for other diseases within 30 days before blood collection, such as drugs used for the treatment of immunorheumatic diseases such as methotrexate, cyclophosphamide, thiazoprine, chlorambucil, etc., drugs for the treatment of breast diseases, such as tamoxifen, etc. 4. History of previous malignant tumors. 5. Having other malignant tumors or multiple primary tumors at the same time.
๐Ÿ’Š

What it tests

  • Proteomics
๐Ÿ“

Where

1 site
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy